Savara Inc. (SVRA)
NMS · Healthcare · Biotechnology
$5.30
-0.38%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$1.09B
Shares Outstanding
205.5M
Exchange
NMS
Currency
USD
About Savara Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (30.3M) | (33.4M) | (38.1M) | (41.0M) |
| Net Income | (29.6M) | (32.2M) | (37.3M) | (40.2M) |
| Diluted EPS | $-0.14 | N/A | $-0.15 | $-0.16 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (38.0M) | (59.2M) | (102.4M) | (122.8M) |
| Net Income | (38.1M) | (54.7M) | (95.9M) | (118.8M) |
| Diluted EPS | $-0.25 | $-0.33 | $-0.48 | $-0.53 |